Prestige Consumer Healthcare Inc.
PBH
NYSE·Healthcare·Medical - Pharmaceuticals·Mkt cap $2.5B
$52.26
▼ -0.57%
P/E
15.42
Mkt Cap
$2.5B
52-Wk Range
$42.62–$71.07
52-Week Range
$42.62 - $71.07
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 20.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Established brand portfolio with high consumer recognition and loyalty
- Efficient multi-channel distribution network across retail, pharmacy, and e-commerce
- Proven acquisition and operational optimization capabilities for underperforming brands
- Diversified product range across multiple therapeutic categories reducing category-specific risk
- Strong cash generation and low capital intensity enabling shareholder returns
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Moderate growth ahead
E-commerce expansion and direct-to-consumer channel growth
Value
Undervalued - trading well below Healthcare Distribution peers
Momentum
Strong
+10.8% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PBH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $0.98 vs $0.89 consensus (+9.6% surprise). Revenue of $265.7M vs $253.0M expected (+5.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+9.6%
Revenue trend · last 8Q
—
—
+3%
+7%
-7%
-3%
-2%
+6%
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q1 27
$267.1M
$283.5M
$290.3M
$296.8M
$249.5M
$274.1M
$283.4M
$265.7M
Margins · last 8Q
Gross
51.3%
Operating
19.8%
Profit
11.0%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Canaccord · May 15, 2026
vs Industry
How PBH stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related